Pugh G W, Tabatabai L B, Bricker B J, Mayfield J E, Phillips M, Zehr E S, Belzer C A
National Animal Disease Center, Agricultural Research Service, USDA, Ames, LA 50010.
Am J Vet Res. 1990 Sep;51(9):1413-20.
A study was conducted to determine whether subcomponent proteins (previously identified as BCSP20, BCSP31, and BCSP45, and the corresponding recombinant proteins rBCSP20, rBCSP31, and rBCSP45) that were recovered from the cell surface of Brucella abortus strain 19 were immunogenic and protective for mice when compared with Brucella cell surface protein (BCSP) and with a proteinase K-treated lipopolysaccharide (PKLPS) extracted from B abortus strain 2308. Protection was evaluated after challenge exposure with a virulent culture of B abortus strain 2308, using CD-1 or BALB/c mice or both inoculated with vaccines of various combinations and concentrations, with and without PKLPS or BCSP. Protection was assessed by enumeration of splenic colony-forming units, reduced mean splenic weight relative to controls, and the relative serologic responses (immune response) in an ELISA. The general results indicate that BCSP, PKLPS, BCSP20, and BCSP31 are immunogenic or protective or both. Protectiveness was not observed for each of the recombinant proteins; however, results from the combined recombinant protein vaccine study suggest the immunogenicity of the recombinant proteins. The apparent immune-inducing properties of BCSP20 and BCSP31 are thought to be attributable to the presence of an immunogenic and protective BCSP fraction (possibly lipopolysaccharide) still associated. Serologic results support our conclusion that each of the recombinant protein vaccines did not induce a protective response comparable to that of BCSP or PKLPS, even when the subcomponents were combined. Although the results suggest that the subcomponents of BCSP apparently induced partial protection, they are thought to be only a part of the antigens contained in BCSP that influence the serologic response.(ABSTRACT TRUNCATED AT 250 WORDS)
开展了一项研究，以确定从流产布鲁氏菌19株细胞表面回收的亚组分蛋白（先前鉴定为BCSP20、BCSP31和BCSP45，以及相应的重组蛋白rBCSP20、rBCSP31和rBCSP45）与布鲁氏菌细胞表面蛋白（BCSP）以及从流产布鲁氏菌2308株提取的蛋白酶K处理的脂多糖（PKLPS）相比，对小鼠是否具有免疫原性和保护性。在用强毒流产布鲁氏菌2308株培养物攻击暴露后，使用接种了各种组合和浓度疫苗的CD-1或BALB/c小鼠或两者，在有和没有PKLPS或BCSP的情况下评估保护作用。通过计数脾脏集落形成单位、相对于对照组降低的平均脾脏重量以及ELISA中的相对血清学反应（免疫反应）来评估保护作用。总体结果表明，BCSP、PKLPS、BCSP20和BCSP31具有免疫原性或保护性或两者兼具。未观察到每种重组蛋白都具有保护作用；然而，联合重组蛋白疫苗研究的结果表明了重组蛋白的免疫原性。BCSP20和BCSP31明显的免疫诱导特性被认为归因于仍然相关的免疫原性和保护性BCSP组分（可能是脂多糖）的存在。血清学结果支持我们的结论，即即使将亚组分组合，每种重组蛋白疫苗也不会诱导出与BCSP或PKLPS相当的保护性反应。虽然结果表明BCSP的亚组分明显诱导了部分保护作用，但它们被认为只是影响血清学反应的BCSP中所含抗原的一部分。（摘要截断于250字）
